Clinical Trial Update: An Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms [NA]

View source ↗

Summary

The UCLA-sponsored open-label, single-arm trial of amisulpride for treatment-resistant schizophrenia and schizoaffective disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Amisulpride (amisulpride)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Schizophrenia, Treatment-Resistant | NA | Status: WITHDRAWN